Arbutus Biopharma Corp (ABUS)

Nasdaq · Pharmaceutical Preparations · Inc. A1

What they're doing

Between 2026-06-21 and 2026-09-19, public records show 1 signal for Arbutus Biopharma Corp. Most notable: 2026-07-16: Filed 8-K disclosing director or officer change. Federal contract obligations over the last 24 months total $0. This summary was assembled automatically from SEC EDGAR, USAspending.gov, U.S. Senate lobbying disclosures and Wikimedia pageview counts.

Generated 2026-09-19 from public records.

Signals, last 12 months

  1. Material 8-K filing
    Filed 8-K disclosing director or officer change
  2. Material 8-K filing
    Filed 8-K disclosing director or officer change
  3. Material 8-K filing
    Filed 8-K disclosing material agreement

Insider transactions

DateInsiderRoleCodeSharesPriceValue
2026-02-02Nguyen TuanofficerA73,5000$0
2026-02-02Androski LindsaydirectorA28,0000$0
2025-02-14Naftzger J. ChristopherofficerA54,3000$0
2025-02-14McElhaugh Michael J.directorA177,0000$0
2025-02-14HASTINGS DAVID CofficerA90,1000$0
2025-02-14Sims KarenofficerA49,3000$0
2025-02-04HASTINGS DAVID CofficerS22,1833.28$72,760
2025-02-04Sims KarenofficerS19,3483.28$63,461
2025-02-04McElhaugh Michael J.directorS23,7903.28$78,031
2025-02-04Naftzger J. ChristopherofficerS11,3333.28$37,172
2024-08-14MANCHESTER KEITH SdirectorS8,8463.69$32,642
2024-08-14MANCHESTER KEITH SdirectorM54,9150.56$30,752

Federal contracts

No federal contract actions on record for this recipient mapping.

Lobbying

No federal lobbying filings on record for this client mapping.

Public attention

7-day average 9 views/day vs 90-day median 8.

Recent filings